160 related articles for article (PubMed ID: 35670093)
1. Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?
Gatto L; Franceschi E; Tosoni A; Nunno VD; Bartolini S; Brandes AA
Immunotherapy; 2022 Jul; 14(10):799-813. PubMed ID: 35670093
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas.
McCord M; Steffens A; Javier R; Kam KL; McCortney K; Horbinski C
Acta Neuropathol Commun; 2020 Feb; 8(1):15. PubMed ID: 32051040
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and therapeutic implications of hypermutation in gliomas.
Touat M; Li YY; Boynton AN; Spurr LF; Iorgulescu JB; Bohrson CL; Cortes-Ciriano I; Birzu C; Geduldig JE; Pelton K; Lim-Fat MJ; Pal S; Ferrer-Luna R; Ramkissoon SH; Dubois F; Bellamy C; Currimjee N; Bonardi J; Qian K; Ho P; Malinowski S; Taquet L; Jones RE; Shetty A; Chow KH; Sharaf R; Pavlick D; Albacker LA; Younan N; Baldini C; Verreault M; Giry M; Guillerm E; Ammari S; Beuvon F; Mokhtari K; Alentorn A; Dehais C; Houillier C; Laigle-Donadey F; Psimaras D; Lee EQ; Nayak L; McFaline-Figueroa JR; Carpentier A; Cornu P; Capelle L; Mathon B; Barnholtz-Sloan JS; Chakravarti A; Bi WL; Chiocca EA; Fehnel KP; Alexandrescu S; Chi SN; Haas-Kogan D; Batchelor TT; Frampton GM; Alexander BM; Huang RY; Ligon AH; Coulet F; Delattre JY; Hoang-Xuan K; Meredith DM; Santagata S; Duval A; Sanson M; Cherniack AD; Wen PY; Reardon DA; Marabelle A; Park PJ; Idbaih A; Beroukhim R; Bandopadhayay P; Bielle F; Ligon KL
Nature; 2020 Apr; 580(7804):517-523. PubMed ID: 32322066
[TBL] [Abstract][Full Text] [Related]
4. Effective Immunotherapy of Glioblastoma in an Adolescent with Constitutional Mismatch Repair-Deficiency Syndrome.
Pavelka Z; Zitterbart K; Nosková H; Bajčiová V; Slabý O; Štěrba J
Klin Onkol; 2019; 32(1):70-74. PubMed ID: 30764633
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibitor failure in hypermutated and mismatch repair-mutated recurrent high-grade gliomas.
Ahmad H; Fadul CE; Schiff D; Purow B
Neurooncol Pract; 2019 Dec; 6(6):424-427. PubMed ID: 31832212
[TBL] [Abstract][Full Text] [Related]
6. Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA).
Almuhaisen G; Alhalaseh Y; Mansour R; Abu-Shanab A; Al-Ghnimat S; Al-Hussaini M
Brain Tumor Pathol; 2021 Jan; 38(1):14-22. PubMed ID: 32897465
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
[TBL] [Abstract][Full Text] [Related]
8. Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade.
Graham LS; Pritchard CC; Schweizer MT
Clin Cancer Res; 2021 Dec; 27(24):6662-6665. PubMed ID: 34580112
[TBL] [Abstract][Full Text] [Related]
9. Mutational burden and immune recognition of gliomas.
Prost D; Bielle F; Ligon KL; Touat M
Curr Opin Oncol; 2021 Nov; 33(6):626-634. PubMed ID: 34651608
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide-associated hypermutation in gliomas.
Choi S; Yu Y; Grimmer MR; Wahl M; Chang SM; Costello JF
Neuro Oncol; 2018 Sep; 20(10):1300-1309. PubMed ID: 29452419
[TBL] [Abstract][Full Text] [Related]
11. Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome.
Yang C; Austin F; Richard H; Idowu M; Williamson V; Sabato F; Ferreira-Gonzalez A; Turner SA
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31604779
[TBL] [Abstract][Full Text] [Related]
12. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.
Hodges TR; Ott M; Xiu J; Gatalica Z; Swensen J; Zhou S; Huse JT; de Groot J; Li S; Overwijk WW; Spetzler D; Heimberger AB
Neuro Oncol; 2017 Aug; 19(8):1047-1057. PubMed ID: 28371827
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
Yu Y; Villanueva-Meyer J; Grimmer MR; Hilz S; Solomon DA; Choi S; Wahl M; Mazor T; Hong C; Shai A; Phillips JJ; Wainer BH; McDermott M; Haas-Kogan D; Taylor JW; Butowski N; Clarke JL; Berger MS; Molinaro AM; Chang SM; Costello JF; Oberheim Bush NA
Neuro Oncol; 2021 Nov; 23(11):1872-1884. PubMed ID: 33823014
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study.
Lombardi G; Barresi V; Indraccolo S; Simbolo M; Fassan M; Mandruzzato S; Simonelli M; Caccese M; Pizzi M; Fassina A; Padovan M; Masetto E; Gardiman MP; Bonavina MG; Caffo M; Persico P; Chioffi F; Denaro L; Dei Tos AP; Scarpa A; Zagonel V
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32823925
[TBL] [Abstract][Full Text] [Related]
15. An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy.
Sibilio P; Belardinilli F; Licursi V; Paci P; Giannini G
Biol Direct; 2022 May; 17(1):10. PubMed ID: 35534873
[TBL] [Abstract][Full Text] [Related]
16. Germline Biallelic Mismatch Repair Deficiency in Childhood Glioblastoma and Implications for Clinical Management.
Mishra AK; Achari RB; Zameer L; Achari G; Gehani A; Roy P; Sudhaman S; Bianchi V; Edwards M; Sen S; Sukumaran RK; Bhattacharyya A; Tabori U; Das A
Neurol India; 2022; 70(2):772-774. PubMed ID: 35532657
[TBL] [Abstract][Full Text] [Related]
17. Hypermutated Gliomas Respond Poorly to Immunotherapy.
Cancer Discov; 2020 Jul; 10(7):OF5. PubMed ID: 32434948
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
Barroso-Sousa R; Jain E; Cohen O; Kim D; Buendia-Buendia J; Winer E; Lin N; Tolaney SM; Wagle N
Ann Oncol; 2020 Mar; 31(3):387-394. PubMed ID: 32067680
[TBL] [Abstract][Full Text] [Related]
19. Input of molecular analysis in medical management of primary brain tumor patients.
Idbaih A; Duran-Peña A; Bonnet C; Ducray F
Rev Neurol (Paris); 2015; 171(6-7):457-65. PubMed ID: 26026669
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome.
Westdorp H; Kolders S; Hoogerbrugge N; de Vries IJM; Jongmans MCJ; Schreibelt G
Cancer Lett; 2017 Sep; 403():159-164. PubMed ID: 28645564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
